Medical device company Integra LifeSciences (NASDAQ:IART) reported Q2 CY2025 results , but sales were flat year on year at ...

Integra Lifesciences Holdings Corp (NASDAQ:IART) is set to release its Q2 2025 earnings on Jul 31, 2025. The consensus ...

Medical device company Integra LifeSciences (NASDAQ:IART) will be reporting results this Thursday before market open. Here’s ...

Although the revenue and EPS for Integra (IART) give a sense of how its business performed in the quarter ended June 2025, it might be worth considering how some key metrics compare with Wall Street ...

Integra LifeSciences (Nasdaq: IART) shares are on the rise today on second-quarter results that beat the consensus forecast.

Integra LifeSciences Holdings Corporation (IART) key stats comparison: compare with other stocks by metrics: valuation, growth, profitability, momentum, EPS revisions, dividends, ratings.

Investors in Integra LifeSciences Holdings Corp (Symbol: IART) saw new options become available this week, for the March 2024 expiration. One of the key inputs that goes into the price an option ...

IART currently has a forward P/E ratio of 18.80, while EW has a forward P/E of 42.86. We also note that IART has a PEG ratio of 1.99. This figure is similar to the commonly-used P/E ratio, with ...

Looking at the chart above, IART's low point in its 52 week range is $27.21 per share, with $52.90 as the 52 week high point — that compares with a last trade of $27.30.

In trading on Thursday, shares of Integra LifeSciences Holdings Corp (NASD: IART) entered into oversold territory, hitting an RSI reading of 25.4, after changing hands as low as $60.53 per share.